Navigation Links
Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses

ent in the off-label patient arm (p=0.048). The TVR rate for on-label patients was 4.5 percent versus 11.6 percent in the off- label patient arm (p=0.040). "These findings are consistent with the overall clinical evidence, which shows complex patients to have higher event rates based on their complexity," he said.

The MATRIX Registry also tracked patient outcomes with dual anti-platelet therapy. According to the results, 75 percent of the patients included in the registry adhered to a prescribed dual antiplatelet therapy out to one year. However, such compliance did not result in significant differences in the rates of mortality, heart attack or stent thrombosis after one year compared to the outcomes of patients who stopped dual anti-platelet therapy before one year.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus-eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at www.cypherstent.com.

About Cord
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
3. Monitoring Patient Glucose Levels: New Advances in software make it easier
4. Managing Preanalytical Processes for Patient Safety
5. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
6. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/28/2015)... , July 20, 2015 ... addition of the "Global Post-traumatic Stress Disorder Therapeutics ... The global PTSD therapeutics market to grow at a ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:7/28/2015)... July 28, 2015 According to a ... Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, ... - Forecast to 2020", published by MarketsandMarkets, the European Injectable ... 2020 from $114.7 Billion in 2015, growing at a CAGR ... 230 market data T ables ...
(Date:7/27/2015)... SEATTLE , July 28, 2015 CTI ... it plans to report its second quarter 2015 financial ... of the U.S. financial markets. Following the announcement, members ... call to discuss the results and provide a general ... Access to the event can be obtained as follows: ...
Breaking Medicine Technology:Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Growing Number of Accidents and Violence Worldwide Drives the Market 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2
... Model of Diabetes with Haptoglobin 2-2 Genotype Show, ... Transport, MONTVALE, N.J., March 31 Synvista,Therapeutics, ... a study of diabetic mice,with the Haptoglobin 2-2 ... Haptoglobin (Hp)-Hemoglobin (Hb) complex may result in a ...
... is now enrolling ... patients, ... announced today the start of a Phase III clinical trial,studying LY450139, an ... LY450139 is being tested,to see if it can slow the progression associated ...
Cached Medicine Technology:Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 2Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 3Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 5Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 6
(Date:7/28/2015)... ... July 28, 2015 , ... ADLINK Technology, a ... edge devices that enable the Internet of Things (IoT), announced its new medical ... to provide exceptional computing power and multitasking capabilities. The MLC 4-21 is completely ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... much-anticipated U.S. commercial launch of its ORTHALIGN PLUS® system, a palm-sized, single-use navigation ... , “OrthAlign successfully combined precision with practicality in a revolutionary way for ...
(Date:7/28/2015)... ... July 28, 2015 , ... On July 16th NPR ... schedule the hearing of proposed bills and laws revolving the implementation of a small ... date. Some vigilante ministers are continuing to hand out clean needles to drug users ...
(Date:7/28/2015)... ... 2015 , ... BiologicsMD, Inc. , a privately held ... of bone disorders and conditions of hair loss, announced that the U.S. Patent ... Binding-Domain and Parathyroid Hormone". The issued patent claims methods of use for promoting ...
(Date:7/28/2015)... ... July 28, 2015 , ... Fertility specialist Dr. Lisa Hasty ... 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has ... colleagues and peers in the metro area as one of the most respected doctors ...
Breaking Medicine News(10 mins):Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 2Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3
... has revealed how change in body temperature impacts the ... Conti of the Scripps Research Institute in La Jolla, ... to prolong life and found that the lifespan of ... core body temperature, reported the health portal News Medical., ...
... meeting on breathing disorders in Paris discussed the ongoing research ... need to revamp the more than a century old test ... which the strains of TB have become resistant. ... the 37th world congress of the Union for breathing health ...
... restaurants to list the calories of all items offered in ... already offered the information regarding calories of various items offered by ... the back of tray liners and in restaurant brochures. ... are resisting the idea. It is a change to be welcomed ...
... Yoga is a path to optimal health by achieving a healthy ... undertaken by many for over 5,000 years//. ,The November ... and its health benefits. ,Yoga has its roots in ... of relaxation, postures and breathing. Several forms of yoga have evolved ...
... 100 health professionals put their heads together to thrash ... is weakening the healthcare system in Queensland. The// representatives ... nuclear medicine technologists in state-run hospitals has warned that ... staff, in the absence of any action. ...
... primary health care for patients that was released by ... developed// countries, except the U.S. ,In the ... it was found that Canada lagged in several aspects ... records, doctors availability after hours, multi-discipline teams for treatment ...
Cached Medicine News:
... assays are designed for ... 2000, a high-throughput, continuous ... IMMULITE 2000 offers testing ... a rapidly expanding menu ...
... from KUBTEC is a dual capability system with ... representation of the specimen under test. While the ... images, the micro focus source also allows the ... standard 2D images. The 100 mm x 100 ...
... specimen radiography. The XPERT represents a research tool ... gray in every digital x-ray image, thus being ... that heretofore were lost to the human eye. ... 2 to 8 x 8 in size, multi-color ...
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
Medicine Products: